you are viewing a single comment's thread.
Glad to hear they got the funding, but wondering about the high interest rate -- 11%. Is that a "normal" rate for bio-techs, or for the purposes of the funds?
That's normal. They must be expecting that it is cheaper to borrow than diluting the shares. May be they can dilute when this hits higher prices and pay off the debt!
Looks like the company is confident now